Barclays’s Abivax ABVX Stock Holding History

Barclays’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$826K	Buy	+6,200	New	+$702K	﹤0.01%	2907
2026 Q1	–	Sell	-500,000	Closed	-$67.4M	–	5003
2025 Q4	$67.4M	Buy	+500,000	New	+$54.6M	0.02%	639

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's ABVX Position: Q2 2026 in Review

Barclays reduced its Abivax (ABVX) stake by 95% in Q2 2026, selling an estimated $9.72M and leaving 4,899 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

Barclays first reported a position in ABVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $41.6M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Barclays held 4,899 shares of Abivax worth $653K as of Q2 2026.
Barclays sold 85,876 Abivax shares in Q2 2026, an estimated $9.72M.
Abivax made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3059 holding.
Barclays first reported a position in Abivax in Q4 2024 and has held it in 7 quarters since.
Barclays's Abivax position peaked at $41.6M in Q4 2025.
303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.